3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
36
Burkitt Lymphoma
30
Leukemia, Biphenotypic, Acute
7
Neoplasm, Residual
6
Leukemia
6
Recurrence
5
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Lymphoma, Non-Hodgkin
3
Blast Crisis
3
Myelodysplastic Syndromes
2
Lymphoma
2
Leukemia, Myelomonocytic, Juvenile
2
Leukemia, Myeloid, Acute
2
Leukemia, Myeloid, Accelerated Phase
2
Leukemia, Myeloid
2
Down Syndrome
2
Sarcoma, Myeloid
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Large Granular Lymphocytic
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Graft vs Host Disease
1
Bites and Stings
1
Interventions
pembrolizumab
2
enzalutamide
2
abiraterone
2
Immune Checkpoint Inhibitors
2
Cytochrome P-450 Enzyme System
2
durvalumab
1
dostarlimab
1
cemiplimab
1
blinatumomab
1
atezolizumab
1
Surgical Instruments
1
Hydroxyurea
1
Etoposide
1
Etanercept
1
Carboplatin
1
Androgen Receptor Antagonists
1
AMG 757
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bites and Stings
×
blinatumomab
×
1 year
×
Clear all
NCT06063317
2026-03-06
OASIS
Imugene Limited
Phase 1
Terminated
25 enrolled